U-Pump

U-Pump: Revolutionizing insulin delivery with precision, AI, and Swiss watch technology for seamless and personalized therapy.

U-Pump has transitioned from the ideation phase to prototype development, with two patents filed and interest from industry leaders like Dexcom. We are preparing for preFDA submission and seeking funding to advance to market-ready status. While we haven't launched commercially, our progress demonstrates market potential and readiness for the next phase.

Our primary customer segments include individuals with diabetes seeking innovative insulin delivery solutions. They are typically located in urban and suburban areas, spanning a wide age range from adolescents to seniors. With an estimated 420 million people globally living with diabetes, the market is vast and growing due to lifestyle changes and an aging population. In the U.S. alone, the market value for insulin delivery devices is projected to reach $11.7 billion by 2025, driven by increasing prevalence and advancements in technology.

U-Pump addresses the significant challenges faced by individuals with insulin-dependent diabetes. Many struggle with the inconvenience and cost of traditional insulin delivery methods, such as injections. Our solution offers a more user-friendly and affordable alternative through an innovative insulin patch pump. The demand for such a solution is evidenced by market research indicating dissatisfaction with current options and the willingness of customers to pay for more convenient and effective alternatives.

U-Pump addresses the critical barriers of cost and convenience in insulin delivery. Our innovative insulin patch pump combines Swiss watch precision with advanced AI technology, offering a user-friendly and cost-effective solution. Key features include the OneMove™ System for easy installation, an AI bolus calculator for personalized dosing, and replaceable cartridges for affordability. This comprehensive approach significantly improves diabetes management, targeting the 80% of insulin-dependent individuals not currently using pumps.

U-Pump faces competition primarily from established insulin pump manufacturers such as Medtronic, Tandem Diabetes Care and Insulet Corporation. These companies have a significant market share in the insulin pump industry. Alternatives to insulin administration include traditional insulin injections and other less advanced insulin pump models. However, U-Pump stands out for its innovative features such as AI bolus calculator, Swiss watch technology, we do not use a setter, our pump has everything on board! This is very important for the client. Affordable subscription model offers customers a unique value proposition. We are building an ecosystem around our user. We are a startup, which means we are dynamic and fast, this is our advantage.

U-Pump boasts several indisputable advantages over competitors, making it a standout choice in the insulin pump market. These include:

OneMove™ System: U-Pump's patented OneMove™ System allows for effortless and painless installation on the body in one motion, eliminating the need for additional equipment like setters.
Replaceable Reservoir: The development of a replaceable reservoir for the patch pump enhances user-friendliness and cost-effectiveness, a feature not commonly found in traditional pump models.
Integration with CGMs and AI Bolus Calculator: Full integration with Continuous Glucose Monitors (CGMs) such as Dexcom or Libra, along with the AI Bolus Calculator, offers personalized dosing recommendations based on real-time glucose levels, providing precise and tailored insulin delivery.
Swiss Watch Technology: Leveraging Swiss watch technology ensures miniature design and necessary energy efficiency, setting U-Pump apart in terms of precision and reliability.
These advantages collectively position U-Pump as a leading choice in the insulin pump market, offering unparalleled convenience, precision, and affordability to users.

In our model, we focus on both providers and patients.
The distribution channel is divided into hospitals, retail pharmacies, online pharmacies, and others.
We offer significantly more favorable conditions, such as a 20% discount, which results in savings of more than $ 1,000 per patient per year.
In the first year of stable operations, we expect to take 1% of the insulin user market in US and expect revenue of $127M
Over 7 years, EBITDA growth will be 182%, customer growth will be 322%
Direct Sales:
"Revenue Growth: Year 1 sees $127M from 36,000 pumps. By Year 5, hit $1.3B.
Direct sales boast an 80% margin."
Subscription model:
"Subscription Revenue: Starts at 6K subscribers, hits 45K by Year 5. At $3,357/year, Year 1 rakes in $20M, scaling to $490M by Year 5.
Steady growth fuels long-term success.

U-Pump operates on a hybrid business model, combining direct sales of our insulin patch pump with a subscription-based service for ongoing support and consumables. Our channels include online sales platforms, partnerships with healthcare providers, and targeted marketing campaigns. Key metrics for success include customer acquisition cost, customer lifetime value, subscription renewal rates, and market penetration.

U-Pump's investment allocation focuses on critical areas to drive growth and innovation:

Product Development: Enhancing the AI bolus calculator, refining the OneMove™ system, and optimizing the Swiss watch technology integration.
Regulatory Compliance: Covering expenses related to preFDA submissions, clinical trials, and obtaining necessary certifications.
Manufacturing Setup: Establishing production facilities and securing equipment for scalable manufacturing of insulin pumps and replaceable reservoirs.
Research and Development: Continued investment in R&D to stay ahead of competitors, improve product features, and explore new innovations.
Operational Expenses: Covering overhead costs, salaries for key personnel, office space, and other administrative expenses.
Legal and IP Protection: Securing patents, trademarks, and legal counsel to protect U-Pump's intellectual property rights and mitigate risks.
By allocating funds strategically across these areas, U-Pump aims to accelerate product development, achieve regulatory milestones, scale manufacturing operations, penetrate target markets effectively, and safeguard its competitive position in the insulin delivery market.

Investment Proposal for U-Pump

Executive Summary: U-Pump is pioneering a transformative approach to diabetes management through an innovative insulin delivery system. Utilizing Swiss precision and advanced AI technology, U-Pump offers a user-friendly and cost-effective solution, designed to significantly increase accessibility for insulin-dependent patients. With a patented OneMove™ System and a strategic subscription model, U-Pump addresses the primary barriers of cost and convenience that have historically limited pump usage among diabetics.

Business Opportunity: The global diabetes epidemic continues to escalate, with over 6 million insulin-dependent Americans in need of effective management solutions. U-Pump’s target market includes individuals who are currently underserved by existing technologies, presenting an immediate opportunity to capture a substantial market share. The convenience and cost-effectiveness of U-Pump’s technology place it at a strategic advantage to become the preferred choice for insulin delivery.

Innovations and Competitive Advantage: U-Pump differentiates itself with several innovative features:
• OneMove™ System: Allows easy and painless attachment of the pump to the body.
• AI Bolus Calculator: Uses real-time data from users to provide personalized dosing recommendations.
• Integration with CGMs: Compatible with leading continuous glucose monitoring systems like Dexcom or Libra.
• Replaceable Reservoirs: Enhances affordability and convenience for patch pump.
These innovations position U-Pump ahead of traditional offerings by Medtronic, Tandem Diabetes Care, and Insulet Corporation, particularly in ease of use and cost.

Financial Projections: In its first year of stable operations, U-Pump projects revenue of $127 million from the sale of 36,000 pumps, with expectations to expand to $1.3 billion by year five due to direct sales and a burgeoning subscriber base. The company boasts an impressive 80% profit margin on direct sales and a robust subscription model projected to grow exponentially.

Funding Request: U-Pump is seeking an initial investment of $1.5 million starting at $500,000, secured via a SAFE with a valuation cap of $15 million. These funds will be utilized to finalize product development, submit for FDA pre-approval, and begin scaling operations.

Use of Funds: The raised funds will specifically be allocated towards:
• Finalizing development and production adjustments based on FDA feedback.
• Covering operational costs and salaries.
• Marketing and pre-market activities including the establishment of a waiting list.

Exit Strategy: Investors can anticipate a return on investment through one of several viable exit strategies, including acquisition by a larger pharmaceutical or medical device company, an IPO, or continued revenue share following full commercialization and scale.

Conclusion: Investing in U-Pump represents a unique opportunity to be part of a revolutionary advancement in diabetes care. With a clear path to the market, a robust product development strategy, and a strong leadership team, U-Pump is poised to deliver significant investor returns while improving the lives of millions worldwide.

While U-Pump is positioned for success, several risks could impact its performance:

Competitive Landscape: Established competitors may introduce similar innovations or lower prices, challenging U-Pump's market share.
Regulatory Hurdles: Delays or denials in obtaining regulatory approvals, such as FDA clearance, could hinder product launch and market entry.
Technological Challenges: Rapid advancements in insulin delivery technology could outpace U-Pump's innovations, making its offerings less attractive.
Market Acceptance: Despite extensive market research, user adoption may not meet expectations due to resistance to change or preferences for established brands.
Economic Conditions: Economic downturns or healthcare policy changes could impact reimbursement rates or consumer spending on medical devices, affecting U-Pump's revenue projections.
Mitigation strategies include continuous monitoring of the competitive landscape, maintaining regulatory compliance readiness, staying abreast of technological advancements, fostering strong customer relationships, and diversifying revenue streams.

We submitted 2 applications to accelerators.
1. YCombinator - Waiting for a solution
2. MassChalenge US (passed to the 2nd round, the decision will be on May 22)
Before this, the founders went through the NUMA France and International Start-Up Program (YEDI) accelerators with previous projects

Application number 63/633,870